nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—CYP3A4—Fingolimod—multiple sclerosis	0.0795	0.246	CbGbCtD
Fulvestrant—CYP3A4—Methylprednisolone—multiple sclerosis	0.0512	0.158	CbGbCtD
Fulvestrant—CYP3A4—Triamcinolone—multiple sclerosis	0.0388	0.12	CbGbCtD
Fulvestrant—CYP3A4—Mitoxantrone—multiple sclerosis	0.0374	0.116	CbGbCtD
Fulvestrant—CYP3A4—Betamethasone—multiple sclerosis	0.0333	0.103	CbGbCtD
Fulvestrant—CYP3A4—Prednisolone—multiple sclerosis	0.0329	0.102	CbGbCtD
Fulvestrant—CYP3A4—Prednisone—multiple sclerosis	0.031	0.096	CbGbCtD
Fulvestrant—CYP3A4—Dexamethasone—multiple sclerosis	0.0194	0.0599	CbGbCtD
Fulvestrant—EPHX2—retina—multiple sclerosis	0.00446	0.12	CbGeAlD
Fulvestrant—ESRRA—medulla oblongata—multiple sclerosis	0.00282	0.0759	CbGeAlD
Fulvestrant—ESRRA—midbrain—multiple sclerosis	0.00258	0.0694	CbGeAlD
Fulvestrant—ESRRA—spinal cord—multiple sclerosis	0.00252	0.0677	CbGeAlD
Fulvestrant—ESR2—brainstem—multiple sclerosis	0.00243	0.0653	CbGeAlD
Fulvestrant—EPHX2—cerebellum—multiple sclerosis	0.00228	0.0613	CbGeAlD
Fulvestrant—ESRRA—nervous system—multiple sclerosis	0.00212	0.057	CbGeAlD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—PGR—multiple sclerosis	0.0021	0.00949	CbGpPWpGaD
Fulvestrant—ESRRA—central nervous system—multiple sclerosis	0.00204	0.0549	CbGeAlD
Fulvestrant—NR1H4—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.00202	0.00913	CbGpPWpGaD
Fulvestrant—ESRRA—cerebellum—multiple sclerosis	0.002	0.0537	CbGeAlD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.00187	0.00845	CbGpPWpGaD
Fulvestrant—EPHX2—brain—multiple sclerosis	0.00185	0.0498	CbGeAlD
Fulvestrant—ESR2—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.00176	0.00795	CbGpPWpGaD
Fulvestrant—NR1H4—Bile acid and bile salt metabolism—ALB—multiple sclerosis	0.00167	0.00756	CbGpPWpGaD
Fulvestrant—ESR1—brainstem—multiple sclerosis	0.00166	0.0447	CbGeAlD
Fulvestrant—NR1H4—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.00166	0.00748	CbGpPWpGaD
Fulvestrant—ESRRA—brain—multiple sclerosis	0.00162	0.0436	CbGeAlD
Fulvestrant—ESR1—Nuclear Receptors—PGR—multiple sclerosis	0.00161	0.00726	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear signaling by ERBB4—PGR—multiple sclerosis	0.00157	0.00711	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.00154	0.00693	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.00154	0.00693	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.00144	0.00651	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.00142	0.0064	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.00142	0.0064	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—SELE—multiple sclerosis	0.00139	0.00626	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—multiple sclerosis	0.00137	0.0062	CbGpPWpGaD
Fulvestrant—NR1H4—RXR and RAR heterodimerization with other nuclear receptor—TNF—multiple sclerosis	0.00128	0.00579	CbGpPWpGaD
Fulvestrant—ESR2—nervous system—multiple sclerosis	0.00127	0.0342	CbGeAlD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—PGR—multiple sclerosis	0.00127	0.00574	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.00123	0.00554	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.00123	0.00554	CbGpPWpGaD
Fulvestrant—ESR2—central nervous system—multiple sclerosis	0.00123	0.0329	CbGeAlD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00122	0.00552	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00122	0.00552	CbGpPWpGaD
Fulvestrant—NR1H4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.00122	0.00551	CbGpPWpGaD
Fulvestrant—ESR2—cerebellum—multiple sclerosis	0.0012	0.0322	CbGeAlD
Fulvestrant—ESR1—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.00113	0.00512	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptors—VDR—multiple sclerosis	0.00112	0.00507	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—ZNF746—multiple sclerosis	0.00109	0.00493	CbGpPWpGaD
Fulvestrant—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.00108	0.00489	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—PGR—multiple sclerosis	0.00106	0.00478	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—MMP9—multiple sclerosis	0.00101	0.00455	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—PTBP1—multiple sclerosis	0.000998	0.00451	CbGpPWpGaD
Fulvestrant—NR1H4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000989	0.00447	CbGpPWpGaD
Fulvestrant—ESR2—brain—multiple sclerosis	0.000973	0.0262	CbGeAlD
Fulvestrant—EPHX2—Metabolism—SRM—multiple sclerosis	0.000971	0.00438	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—ZMIZ1—multiple sclerosis	0.000968	0.00437	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000918	0.00414	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000897	0.00405	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000897	0.00405	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear Receptor transcription pathway—VDR—multiple sclerosis	0.000888	0.00401	CbGpPWpGaD
Fulvestrant—ESR1—nervous system—multiple sclerosis	0.000872	0.0234	CbGeAlD
Fulvestrant—ESR1—central nervous system—multiple sclerosis	0.000839	0.0226	CbGeAlD
Fulvestrant—ESR1—cerebellum—multiple sclerosis	0.00082	0.0221	CbGeAlD
Fulvestrant—NR1H4—Gene Expression—ZNF746—multiple sclerosis	0.000797	0.0036	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000777	0.00351	CbGpPWpGaD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000777	0.00351	CbGpPWpGaD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000777	0.00351	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—SRM—multiple sclerosis	0.000776	0.0035	CbGpPWpGaD
Fulvestrant—Dermatitis—Cladribine—multiple sclerosis	0.000773	0.00185	CcSEcCtD
Fulvestrant—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000772	0.00185	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—IFNB1—multiple sclerosis	0.000772	0.00349	CbGpPWpGaD
Fulvestrant—Anorexia—Mitoxantrone—multiple sclerosis	0.000769	0.00184	CcSEcCtD
Fulvestrant—Headache—Cladribine—multiple sclerosis	0.000769	0.00184	CcSEcCtD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000766	0.00346	CbGpPWpGaD
Fulvestrant—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000766	0.00346	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—HNRNPA1—multiple sclerosis	0.000756	0.00342	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—U2AF2—multiple sclerosis	0.000756	0.00342	CbGpPWpGaD
Fulvestrant—Depression—Prednisone—multiple sclerosis	0.000752	0.0018	CcSEcCtD
Fulvestrant—Malnutrition—Methylprednisolone—multiple sclerosis	0.000744	0.00178	CcSEcCtD
Fulvestrant—Angioedema—Prednisolone—multiple sclerosis	0.000741	0.00177	CcSEcCtD
Fulvestrant—Breast disorder—Methotrexate—multiple sclerosis	0.000739	0.00177	CcSEcCtD
Fulvestrant—Hypersensitivity—Azathioprine—multiple sclerosis	0.000736	0.00176	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000735	0.00176	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000733	0.00331	CbGpPWpGaD
Fulvestrant—Nausea—Cladribine—multiple sclerosis	0.000729	0.00174	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—PTBP1—multiple sclerosis	0.000729	0.00329	CbGpPWpGaD
Fulvestrant—Vertigo—Prednisolone—multiple sclerosis	0.000729	0.00174	CcSEcCtD
Fulvestrant—ESR1—Generic Transcription Pathway—ZNF746—multiple sclerosis	0.000727	0.00328	CbGpPWpGaD
Fulvestrant—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000725	0.00173	CcSEcCtD
Fulvestrant—Back pain—Triamcinolone—multiple sclerosis	0.000722	0.00173	CcSEcCtD
Fulvestrant—Dyspnoea—Mitoxantrone—multiple sclerosis	0.00072	0.00172	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000715	0.00323	CbGpPWpGaD
Fulvestrant—Dyspepsia—Mitoxantrone—multiple sclerosis	0.00071	0.0017	CcSEcCtD
Fulvestrant—Angiopathy—Dexamethasone—multiple sclerosis	0.000706	0.00169	CcSEcCtD
Fulvestrant—Angiopathy—Betamethasone—multiple sclerosis	0.000706	0.00169	CcSEcCtD
Fulvestrant—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000702	0.00168	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.0007	0.00316	CbGpPWpGaD
Fulvestrant—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000697	0.00315	CbGpPWpGaD
Fulvestrant—Fatigue—Mitoxantrone—multiple sclerosis	0.000696	0.00166	CcSEcCtD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000695	0.00314	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—ZNF746—multiple sclerosis	0.000694	0.00314	CbGpPWpGaD
Fulvestrant—Pain—Mitoxantrone—multiple sclerosis	0.00069	0.00165	CcSEcCtD
Fulvestrant—Constipation—Mitoxantrone—multiple sclerosis	0.00069	0.00165	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—CYP27B1—multiple sclerosis	0.000684	0.00309	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—CYP24A1—multiple sclerosis	0.000684	0.00309	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—PGR—multiple sclerosis	0.000684	0.00309	CbGpPWpGaD
Fulvestrant—Diarrhoea—Azathioprine—multiple sclerosis	0.000683	0.00163	CcSEcCtD
Fulvestrant—Angioedema—Triamcinolone—multiple sclerosis	0.000682	0.00163	CcSEcCtD
Fulvestrant—Haemoglobin—Prednisone—multiple sclerosis	0.000681	0.00163	CcSEcCtD
Fulvestrant—Angioedema—Methylprednisolone—multiple sclerosis	0.00068	0.00163	CcSEcCtD
Fulvestrant—Haemorrhage—Prednisone—multiple sclerosis	0.000677	0.00162	CcSEcCtD
Fulvestrant—Vertigo—Triamcinolone—multiple sclerosis	0.00067	0.0016	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—IL10—multiple sclerosis	0.00067	0.00303	CbGpPWpGaD
Fulvestrant—Vertigo—Methylprednisolone—multiple sclerosis	0.000669	0.0016	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000668	0.00302	CbGpPWpGaD
Fulvestrant—ESR1—brain—multiple sclerosis	0.000666	0.0179	CbGeAlD
Fulvestrant—Connective tissue disorder—Prednisone—multiple sclerosis	0.000666	0.00159	CcSEcCtD
Fulvestrant—Dizziness—Azathioprine—multiple sclerosis	0.00066	0.00158	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.00066	0.00158	CcSEcCtD
Fulvestrant—ESR1—Estrogen signaling pathway—MAPK1—multiple sclerosis	0.000653	0.00295	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—IL4—multiple sclerosis	0.000652	0.00294	CbGpPWpGaD
Fulvestrant—Cough—Triamcinolone—multiple sclerosis	0.000651	0.00156	CcSEcCtD
Fulvestrant—Urticaria—Mitoxantrone—multiple sclerosis	0.000641	0.00153	CcSEcCtD
Fulvestrant—Hyperhidrosis—Prednisolone—multiple sclerosis	0.00064	0.00153	CcSEcCtD
Fulvestrant—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000638	0.00153	CcSEcCtD
Fulvestrant—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000638	0.00153	CcSEcCtD
Fulvestrant—Myalgia—Triamcinolone—multiple sclerosis	0.000635	0.00152	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—PTBP1—multiple sclerosis	0.000635	0.00287	CbGpPWpGaD
Fulvestrant—Vomiting—Azathioprine—multiple sclerosis	0.000635	0.00152	CcSEcCtD
Fulvestrant—Myalgia—Methylprednisolone—multiple sclerosis	0.000634	0.00152	CcSEcCtD
Fulvestrant—Arthralgia—Methylprednisolone—multiple sclerosis	0.000634	0.00152	CcSEcCtD
Fulvestrant—Anxiety—Methylprednisolone—multiple sclerosis	0.000632	0.00151	CcSEcCtD
Fulvestrant—Infestation NOS—Methotrexate—multiple sclerosis	0.00063	0.00151	CcSEcCtD
Fulvestrant—Infestation—Methotrexate—multiple sclerosis	0.00063	0.00151	CcSEcCtD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00063	0.00284	CbGpPWpGaD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00063	0.00284	CbGpPWpGaD
Fulvestrant—Rash—Azathioprine—multiple sclerosis	0.000629	0.00151	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000629	0.00151	CcSEcCtD
Fulvestrant—Dermatitis—Azathioprine—multiple sclerosis	0.000629	0.0015	CcSEcCtD
Fulvestrant—Depression—Methotrexate—multiple sclerosis	0.000629	0.0015	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—GPC5—multiple sclerosis	0.000625	0.00282	CbGpPWpGaD
Fulvestrant—Headache—Azathioprine—multiple sclerosis	0.000625	0.0015	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000624	0.00282	CbGpPWpGaD
Fulvestrant—Angioedema—Betamethasone—multiple sclerosis	0.000619	0.00148	CcSEcCtD
Fulvestrant—Angioedema—Dexamethasone—multiple sclerosis	0.000619	0.00148	CcSEcCtD
Fulvestrant—Angiopathy—Prednisone—multiple sclerosis	0.000614	0.00147	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—VDR—multiple sclerosis	0.000613	0.00277	CbGpPWpGaD
Fulvestrant—Immune system disorder—Prednisone—multiple sclerosis	0.000612	0.00146	CcSEcCtD
Fulvestrant—Vertigo—Dexamethasone—multiple sclerosis	0.000608	0.00146	CcSEcCtD
Fulvestrant—Vertigo—Betamethasone—multiple sclerosis	0.000608	0.00146	CcSEcCtD
Fulvestrant—Infection—Triamcinolone—multiple sclerosis	0.000605	0.00145	CcSEcCtD
Fulvestrant—Sweating—Methotrexate—multiple sclerosis	0.000604	0.00145	CcSEcCtD
Fulvestrant—Infection—Methylprednisolone—multiple sclerosis	0.000604	0.00144	CcSEcCtD
Fulvestrant—Insomnia—Prednisolone—multiple sclerosis	0.000599	0.00143	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—ZFP36L1—multiple sclerosis	0.000598	0.0027	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—IL10—multiple sclerosis	0.000596	0.00269	CbGpPWpGaD
Fulvestrant—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000596	0.00143	CcSEcCtD
Fulvestrant—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000596	0.00143	CcSEcCtD
Fulvestrant—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000595	0.00142	CcSEcCtD
Fulvestrant—Paraesthesia—Prednisolone—multiple sclerosis	0.000595	0.00142	CcSEcCtD
Fulvestrant—Nausea—Azathioprine—multiple sclerosis	0.000593	0.00142	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—HLA-A—multiple sclerosis	0.000591	0.00267	CbGpPWpGaD
Fulvestrant—Skin disorder—Methylprednisolone—multiple sclerosis	0.00059	0.00141	CcSEcCtD
Fulvestrant—Malnutrition—Prednisone—multiple sclerosis	0.00059	0.00141	CcSEcCtD
Fulvestrant—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000589	0.00141	CcSEcCtD
Fulvestrant—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000587	0.00141	CcSEcCtD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—MYC—multiple sclerosis	0.000583	0.00263	CbGpPWpGaD
Fulvestrant—Asthenia—Mitoxantrone—multiple sclerosis	0.000579	0.00139	CcSEcCtD
Fulvestrant—Myalgia—Dexamethasone—multiple sclerosis	0.000576	0.00138	CcSEcCtD
Fulvestrant—Myalgia—Betamethasone—multiple sclerosis	0.000576	0.00138	CcSEcCtD
Fulvestrant—Anxiety—Betamethasone—multiple sclerosis	0.000574	0.00137	CcSEcCtD
Fulvestrant—Anxiety—Dexamethasone—multiple sclerosis	0.000574	0.00137	CcSEcCtD
Fulvestrant—Haemoglobin—Methotrexate—multiple sclerosis	0.000569	0.00136	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—SRM—multiple sclerosis	0.000567	0.00256	CbGpPWpGaD
Fulvestrant—Pain—Prednisolone—multiple sclerosis	0.000566	0.00135	CcSEcCtD
Fulvestrant—Haemorrhage—Methotrexate—multiple sclerosis	0.000566	0.00135	CcSEcCtD
Fulvestrant—Hepatitis—Methotrexate—multiple sclerosis	0.000566	0.00135	CcSEcCtD
Fulvestrant—Pharyngitis—Methotrexate—multiple sclerosis	0.000562	0.00134	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000555	0.00133	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000554	0.00132	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—HNRNPA1—multiple sclerosis	0.000553	0.0025	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—U2AF2—multiple sclerosis	0.000553	0.0025	CbGpPWpGaD
Fulvestrant—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000552	0.00132	CcSEcCtD
Fulvestrant—Insomnia—Triamcinolone—multiple sclerosis	0.000551	0.00132	CcSEcCtD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—AQP4—multiple sclerosis	0.00055	0.00248	CbGpPWpGaD
Fulvestrant—Insomnia—Methylprednisolone—multiple sclerosis	0.00055	0.00131	CcSEcCtD
Fulvestrant—Infection—Betamethasone—multiple sclerosis	0.000549	0.00131	CcSEcCtD
Fulvestrant—Infection—Dexamethasone—multiple sclerosis	0.000549	0.00131	CcSEcCtD
Fulvestrant—Paraesthesia—Triamcinolone—multiple sclerosis	0.000547	0.00131	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—CYP24A1—multiple sclerosis	0.000547	0.00247	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—CYP27B1—multiple sclerosis	0.000547	0.00247	CbGpPWpGaD
Fulvestrant—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000546	0.00131	CcSEcCtD
Fulvestrant—Anaemia—Prednisone—multiple sclerosis	0.000545	0.0013	CcSEcCtD
Fulvestrant—Dyspnoea—Triamcinolone—multiple sclerosis	0.000543	0.0013	CcSEcCtD
Fulvestrant—Nervous system disorder—Betamethasone—multiple sclerosis	0.000542	0.0013	CcSEcCtD
Fulvestrant—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000542	0.0013	CcSEcCtD
Fulvestrant—Angioedema—Prednisone—multiple sclerosis	0.000539	0.00129	CcSEcCtD
Fulvestrant—Dyspepsia—Triamcinolone—multiple sclerosis	0.000536	0.00128	CcSEcCtD
Fulvestrant—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000535	0.00128	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000534	0.00241	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000534	0.00128	CcSEcCtD
Fulvestrant—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000534	0.00128	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000534	0.00241	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—PGR—multiple sclerosis	0.00053	0.00239	CbGpPWpGaD
Fulvestrant—Vertigo—Prednisone—multiple sclerosis	0.00053	0.00127	CcSEcCtD
Fulvestrant—Anorexia—Betamethasone—multiple sclerosis	0.000527	0.00126	CcSEcCtD
Fulvestrant—Anorexia—Dexamethasone—multiple sclerosis	0.000527	0.00126	CcSEcCtD
Fulvestrant—Urticaria—Prednisolone—multiple sclerosis	0.000526	0.00126	CcSEcCtD
Fulvestrant—NR1H4—Biological oxidations—POMC—multiple sclerosis	0.000526	0.00237	CbGpPWpGaD
Fulvestrant—Fatigue—Triamcinolone—multiple sclerosis	0.000525	0.00126	CcSEcCtD
Fulvestrant—Fatigue—Methylprednisolone—multiple sclerosis	0.000524	0.00125	CcSEcCtD
Fulvestrant—Pain—Triamcinolone—multiple sclerosis	0.000521	0.00125	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—RRM1—multiple sclerosis	0.000518	0.00234	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CD28—multiple sclerosis	0.000515	0.00233	CbGpPWpGaD
Fulvestrant—Angiopathy—Methotrexate—multiple sclerosis	0.000514	0.00123	CcSEcCtD
Fulvestrant—Vomiting—Mitoxantrone—multiple sclerosis	0.000513	0.00123	CcSEcCtD
Fulvestrant—Immune system disorder—Methotrexate—multiple sclerosis	0.000511	0.00122	CcSEcCtD
Fulvestrant—Rash—Mitoxantrone—multiple sclerosis	0.000509	0.00122	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—MMP9—multiple sclerosis	0.000508	0.0023	CbGpPWpGaD
Fulvestrant—Dermatitis—Mitoxantrone—multiple sclerosis	0.000508	0.00122	CcSEcCtD
Fulvestrant—Headache—Mitoxantrone—multiple sclerosis	0.000506	0.00121	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000503	0.0012	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000503	0.0012	CcSEcCtD
Fulvestrant—Myalgia—Prednisone—multiple sclerosis	0.000502	0.0012	CcSEcCtD
Fulvestrant—Arthralgia—Prednisone—multiple sclerosis	0.000502	0.0012	CcSEcCtD
Fulvestrant—Anxiety—Prednisone—multiple sclerosis	0.0005	0.0012	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—GPC5—multiple sclerosis	0.0005	0.00226	CbGpPWpGaD
Fulvestrant—Insomnia—Dexamethasone—multiple sclerosis	0.0005	0.0012	CcSEcCtD
Fulvestrant—Insomnia—Betamethasone—multiple sclerosis	0.0005	0.0012	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—PGR—multiple sclerosis	0.0005	0.00226	CbGpPWpGaD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000498	0.00119	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000497	0.00119	CcSEcCtD
Fulvestrant—Paraesthesia—Dexamethasone—multiple sclerosis	0.000496	0.00119	CcSEcCtD
Fulvestrant—Paraesthesia—Betamethasone—multiple sclerosis	0.000496	0.00119	CcSEcCtD
Fulvestrant—Malnutrition—Methotrexate—multiple sclerosis	0.000493	0.00118	CcSEcCtD
Fulvestrant—Hypersensitivity—Prednisolone—multiple sclerosis	0.000488	0.00117	CcSEcCtD
Fulvestrant—CYP3A4—nervous system—multiple sclerosis	0.000486	0.0131	CbGeAlD
Fulvestrant—Dyspepsia—Betamethasone—multiple sclerosis	0.000486	0.00116	CcSEcCtD
Fulvestrant—Dyspepsia—Dexamethasone—multiple sclerosis	0.000486	0.00116	CcSEcCtD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	0.000486	0.00219	CbGpPWpGaD
Fulvestrant—Urticaria—Triamcinolone—multiple sclerosis	0.000484	0.00116	CcSEcCtD
Fulvestrant—Urticaria—Methylprednisolone—multiple sclerosis	0.000483	0.00115	CcSEcCtD
Fulvestrant—Body temperature increased—Triamcinolone—multiple sclerosis	0.000481	0.00115	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—HNRNPA1—multiple sclerosis	0.000481	0.00217	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—U2AF2—multiple sclerosis	0.000481	0.00217	CbGpPWpGaD
Fulvestrant—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00048	0.00115	CcSEcCtD
Fulvestrant—Decreased appetite—Dexamethasone—multiple sclerosis	0.00048	0.00115	CcSEcCtD
Fulvestrant—Decreased appetite—Betamethasone—multiple sclerosis	0.00048	0.00115	CcSEcCtD
Fulvestrant—Nausea—Mitoxantrone—multiple sclerosis	0.000479	0.00115	CcSEcCtD
Fulvestrant—Infection—Prednisone—multiple sclerosis	0.000478	0.00114	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—VDR—multiple sclerosis	0.000478	0.00216	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000477	0.00114	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000477	0.00114	CcSEcCtD
Fulvestrant—Back pain—Methotrexate—multiple sclerosis	0.000477	0.00114	CcSEcCtD
Fulvestrant—Fatigue—Betamethasone—multiple sclerosis	0.000476	0.00114	CcSEcCtD
Fulvestrant—Fatigue—Dexamethasone—multiple sclerosis	0.000476	0.00114	CcSEcCtD
Fulvestrant—Pain—Dexamethasone—multiple sclerosis	0.000472	0.00113	CcSEcCtD
Fulvestrant—Pain—Betamethasone—multiple sclerosis	0.000472	0.00113	CcSEcCtD
Fulvestrant—Nervous system disorder—Prednisone—multiple sclerosis	0.000472	0.00113	CcSEcCtD
Fulvestrant—CYP3A4—central nervous system—multiple sclerosis	0.000468	0.0126	CbGeAlD
Fulvestrant—Skin disorder—Prednisone—multiple sclerosis	0.000467	0.00112	CcSEcCtD
Fulvestrant—Hyperhidrosis—Prednisone—multiple sclerosis	0.000465	0.00111	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—PABPC1—multiple sclerosis	0.000464	0.00209	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CCL2—multiple sclerosis	0.000464	0.00209	CbGpPWpGaD
Fulvestrant—Anorexia—Prednisone—multiple sclerosis	0.000459	0.0011	CcSEcCtD
Fulvestrant—Anaemia—Methotrexate—multiple sclerosis	0.000455	0.00109	CcSEcCtD
Fulvestrant—ESR1—ATF-2 transcription factor network—IFNG—multiple sclerosis	0.000452	0.00204	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000452	0.00108	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000452	0.00108	CcSEcCtD
Fulvestrant—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000449	0.00107	CcSEcCtD
Fulvestrant—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000448	0.00107	CcSEcCtD
Fulvestrant—Vertigo—Methotrexate—multiple sclerosis	0.000443	0.00106	CcSEcCtD
Fulvestrant—Leukopenia—Methotrexate—multiple sclerosis	0.000441	0.00106	CcSEcCtD
Fulvestrant—Urticaria—Betamethasone—multiple sclerosis	0.000439	0.00105	CcSEcCtD
Fulvestrant—Urticaria—Dexamethasone—multiple sclerosis	0.000439	0.00105	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000438	0.00105	CcSEcCtD
Fulvestrant—Dizziness—Prednisolone—multiple sclerosis	0.000438	0.00105	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—ZFP36L1—multiple sclerosis	0.000437	0.00197	CbGpPWpGaD
Fulvestrant—Asthenia—Triamcinolone—multiple sclerosis	0.000437	0.00105	CcSEcCtD
Fulvestrant—Abdominal pain—Dexamethasone—multiple sclerosis	0.000437	0.00104	CcSEcCtD
Fulvestrant—Abdominal pain—Betamethasone—multiple sclerosis	0.000437	0.00104	CcSEcCtD
Fulvestrant—Body temperature increased—Dexamethasone—multiple sclerosis	0.000437	0.00104	CcSEcCtD
Fulvestrant—Body temperature increased—Betamethasone—multiple sclerosis	0.000437	0.00104	CcSEcCtD
Fulvestrant—Asthenia—Methylprednisolone—multiple sclerosis	0.000436	0.00104	CcSEcCtD
Fulvestrant—Insomnia—Prednisone—multiple sclerosis	0.000435	0.00104	CcSEcCtD
Fulvestrant—ESR2—Generic Transcription Pathway—PGR—multiple sclerosis	0.000435	0.00196	CbGpPWpGaD
Fulvestrant—Paraesthesia—Prednisone—multiple sclerosis	0.000432	0.00103	CcSEcCtD
Fulvestrant—Pruritus—Triamcinolone—multiple sclerosis	0.000431	0.00103	CcSEcCtD
Fulvestrant—Cough—Methotrexate—multiple sclerosis	0.00043	0.00103	CcSEcCtD
Fulvestrant—Pruritus—Methylprednisolone—multiple sclerosis	0.00043	0.00103	CcSEcCtD
Fulvestrant—Dyspepsia—Prednisone—multiple sclerosis	0.000424	0.00101	CcSEcCtD
Fulvestrant—Myalgia—Methotrexate—multiple sclerosis	0.000419	0.001	CcSEcCtD
Fulvestrant—Arthralgia—Methotrexate—multiple sclerosis	0.000419	0.001	CcSEcCtD
Fulvestrant—Chest pain—Methotrexate—multiple sclerosis	0.000419	0.001	CcSEcCtD
Fulvestrant—Decreased appetite—Prednisone—multiple sclerosis	0.000418	0.001	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—RPL5—multiple sclerosis	0.000418	0.00189	CbGpPWpGaD
Fulvestrant—Rash—Prednisolone—multiple sclerosis	0.000417	0.000999	CcSEcCtD
Fulvestrant—Dermatitis—Prednisolone—multiple sclerosis	0.000417	0.000998	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000417	0.000997	CcSEcCtD
Fulvestrant—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000416	0.000994	CcSEcCtD
Fulvestrant—Fatigue—Prednisone—multiple sclerosis	0.000415	0.000992	CcSEcCtD
Fulvestrant—Headache—Prednisolone—multiple sclerosis	0.000415	0.000992	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—RRM1—multiple sclerosis	0.000414	0.00187	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—MYC—multiple sclerosis	0.000412	0.00186	CbGpPWpGaD
Fulvestrant—Constipation—Prednisone—multiple sclerosis	0.000411	0.000984	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—MYC—multiple sclerosis	0.000404	0.00183	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—IFNG—multiple sclerosis	0.000403	0.00182	CbGpPWpGaD
Fulvestrant—Dizziness—Triamcinolone—multiple sclerosis	0.000403	0.000963	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000402	0.00182	CbGpPWpGaD
Fulvestrant—Dizziness—Methylprednisolone—multiple sclerosis	0.000402	0.000961	CcSEcCtD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.0004	0.00181	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP24A1—multiple sclerosis	0.0004	0.0018	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—CYP27B1—multiple sclerosis	0.0004	0.0018	CbGpPWpGaD
Fulvestrant—Infection—Methotrexate—multiple sclerosis	0.000399	0.000956	CcSEcCtD
Fulvestrant—Asthenia—Betamethasone—multiple sclerosis	0.000396	0.000948	CcSEcCtD
Fulvestrant—Asthenia—Dexamethasone—multiple sclerosis	0.000396	0.000948	CcSEcCtD
Fulvestrant—Nervous system disorder—Methotrexate—multiple sclerosis	0.000394	0.000943	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—IFNG—multiple sclerosis	0.000394	0.00178	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000393	0.000941	CcSEcCtD
Fulvestrant—Nausea—Prednisolone—multiple sclerosis	0.000393	0.000941	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000392	0.00177	CbGpPWpGaD
Fulvestrant—Pruritus—Betamethasone—multiple sclerosis	0.000391	0.000935	CcSEcCtD
Fulvestrant—Pruritus—Dexamethasone—multiple sclerosis	0.000391	0.000935	CcSEcCtD
Fulvestrant—Skin disorder—Methotrexate—multiple sclerosis	0.000391	0.000934	CcSEcCtD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.00039	0.00176	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000389	0.00093	CcSEcCtD
Fulvestrant—Vomiting—Triamcinolone—multiple sclerosis	0.000387	0.000926	CcSEcCtD
Fulvestrant—Vomiting—Methylprednisolone—multiple sclerosis	0.000386	0.000924	CcSEcCtD
Fulvestrant—Rash—Triamcinolone—multiple sclerosis	0.000384	0.000918	CcSEcCtD
Fulvestrant—Dermatitis—Triamcinolone—multiple sclerosis	0.000384	0.000918	CcSEcCtD
Fulvestrant—Anorexia—Methotrexate—multiple sclerosis	0.000383	0.000917	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000383	0.00173	CbGpPWpGaD
Fulvestrant—Rash—Methylprednisolone—multiple sclerosis	0.000383	0.000916	CcSEcCtD
Fulvestrant—Dermatitis—Methylprednisolone—multiple sclerosis	0.000383	0.000916	CcSEcCtD
Fulvestrant—Urticaria—Prednisone—multiple sclerosis	0.000382	0.000914	CcSEcCtD
Fulvestrant—Headache—Triamcinolone—multiple sclerosis	0.000381	0.000913	CcSEcCtD
Fulvestrant—Headache—Methylprednisolone—multiple sclerosis	0.000381	0.000911	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—ZFP36L1—multiple sclerosis	0.00038	0.00172	CbGpPWpGaD
Fulvestrant—Abdominal pain—Prednisone—multiple sclerosis	0.00038	0.00091	CcSEcCtD
Fulvestrant—Body temperature increased—Prednisone—multiple sclerosis	0.00038	0.00091	CcSEcCtD
Fulvestrant—Diarrhoea—Dexamethasone—multiple sclerosis	0.000378	0.000904	CcSEcCtD
Fulvestrant—Diarrhoea—Betamethasone—multiple sclerosis	0.000378	0.000904	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000375	0.00169	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CD86—multiple sclerosis	0.000368	0.00166	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000367	0.00166	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000366	0.000876	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—GPC5—multiple sclerosis	0.000365	0.00165	CbGpPWpGaD
Fulvestrant—Dizziness—Dexamethasone—multiple sclerosis	0.000365	0.000874	CcSEcCtD
Fulvestrant—Dizziness—Betamethasone—multiple sclerosis	0.000365	0.000874	CcSEcCtD
Fulvestrant—Insomnia—Methotrexate—multiple sclerosis	0.000364	0.00087	CcSEcCtD
Fulvestrant—Nausea—Triamcinolone—multiple sclerosis	0.000362	0.000865	CcSEcCtD
Fulvestrant—Paraesthesia—Methotrexate—multiple sclerosis	0.000361	0.000864	CcSEcCtD
Fulvestrant—Nausea—Methylprednisolone—multiple sclerosis	0.000361	0.000863	CcSEcCtD
Fulvestrant—Dyspnoea—Methotrexate—multiple sclerosis	0.000358	0.000858	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—IL2—multiple sclerosis	0.000358	0.00162	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000357	0.00161	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Prednisone—multiple sclerosis	0.000354	0.000848	CcSEcCtD
Fulvestrant—Dyspepsia—Methotrexate—multiple sclerosis	0.000354	0.000847	CcSEcCtD
Fulvestrant—Vomiting—Betamethasone—multiple sclerosis	0.000351	0.00084	CcSEcCtD
Fulvestrant—Vomiting—Dexamethasone—multiple sclerosis	0.000351	0.00084	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—IL2—multiple sclerosis	0.00035	0.00158	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—ZNF746—multiple sclerosis	0.00035	0.00158	CbGpPWpGaD
Fulvestrant—Decreased appetite—Methotrexate—multiple sclerosis	0.00035	0.000836	CcSEcCtD
Fulvestrant—NR1H4—Generic Transcription Pathway—VDR—multiple sclerosis	0.000349	0.00158	CbGpPWpGaD
Fulvestrant—Rash—Dexamethasone—multiple sclerosis	0.000348	0.000833	CcSEcCtD
Fulvestrant—Rash—Betamethasone—multiple sclerosis	0.000348	0.000833	CcSEcCtD
Fulvestrant—Dermatitis—Betamethasone—multiple sclerosis	0.000348	0.000833	CcSEcCtD
Fulvestrant—Dermatitis—Dexamethasone—multiple sclerosis	0.000348	0.000833	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000347	0.000831	CcSEcCtD
Fulvestrant—Fatigue—Methotrexate—multiple sclerosis	0.000347	0.000829	CcSEcCtD
Fulvestrant—Headache—Betamethasone—multiple sclerosis	0.000346	0.000828	CcSEcCtD
Fulvestrant—Headache—Dexamethasone—multiple sclerosis	0.000346	0.000828	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000345	0.00156	CbGpPWpGaD
Fulvestrant—Asthenia—Prednisone—multiple sclerosis	0.000345	0.000826	CcSEcCtD
Fulvestrant—Pain—Methotrexate—multiple sclerosis	0.000344	0.000823	CcSEcCtD
Fulvestrant—Pruritus—Prednisone—multiple sclerosis	0.00034	0.000814	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—PABPC1—multiple sclerosis	0.000339	0.00153	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000334	0.00151	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000334	0.00151	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—IL1B—multiple sclerosis	0.000333	0.0015	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MMP9—multiple sclerosis	0.000331	0.0015	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00033	0.00149	CbGpPWpGaD
Fulvestrant—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00033	0.00149	CbGpPWpGaD
Fulvestrant—Diarrhoea—Prednisone—multiple sclerosis	0.000329	0.000788	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—PGR—multiple sclerosis	0.000329	0.00149	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000329	0.000787	CcSEcCtD
Fulvestrant—Nausea—Betamethasone—multiple sclerosis	0.000328	0.000785	CcSEcCtD
Fulvestrant—Nausea—Dexamethasone—multiple sclerosis	0.000328	0.000785	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000321	0.00145	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PTBP1—multiple sclerosis	0.00032	0.00145	CbGpPWpGaD
Fulvestrant—Urticaria—Methotrexate—multiple sclerosis	0.000319	0.000764	CcSEcCtD
Fulvestrant—Dizziness—Prednisone—multiple sclerosis	0.000318	0.000761	CcSEcCtD
Fulvestrant—Body temperature increased—Methotrexate—multiple sclerosis	0.000318	0.00076	CcSEcCtD
Fulvestrant—Abdominal pain—Methotrexate—multiple sclerosis	0.000318	0.00076	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000315	0.00142	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000315	0.00142	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—MAPK1—multiple sclerosis	0.000307	0.00139	CbGpPWpGaD
Fulvestrant—Vomiting—Prednisone—multiple sclerosis	0.000306	0.000732	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—RPL5—multiple sclerosis	0.000306	0.00138	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—VDR—multiple sclerosis	0.000304	0.00137	CbGpPWpGaD
Fulvestrant—Rash—Prednisone—multiple sclerosis	0.000303	0.000726	CcSEcCtD
Fulvestrant—Dermatitis—Prednisone—multiple sclerosis	0.000303	0.000725	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—RRM1—multiple sclerosis	0.000303	0.00137	CbGpPWpGaD
Fulvestrant—Headache—Prednisone—multiple sclerosis	0.000301	0.000721	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—BCHE—multiple sclerosis	0.000298	0.00134	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Methotrexate—multiple sclerosis	0.000296	0.000709	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—PABPC1—multiple sclerosis	0.000295	0.00133	CbGpPWpGaD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—MYC—multiple sclerosis	0.000294	0.00133	CbGpPWpGaD
Fulvestrant—Asthenia—Methotrexate—multiple sclerosis	0.000289	0.00069	CcSEcCtD
Fulvestrant—Nausea—Prednisone—multiple sclerosis	0.000286	0.000684	CcSEcCtD
Fulvestrant—Pruritus—Methotrexate—multiple sclerosis	0.000284	0.000681	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—MYC—multiple sclerosis	0.00028	0.00127	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—TGFB1—multiple sclerosis	0.00028	0.00126	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—STAT3—multiple sclerosis	0.000279	0.00126	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000276	0.00125	CbGpPWpGaD
Fulvestrant—Diarrhoea—Methotrexate—multiple sclerosis	0.000275	0.000658	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—MAPK1—multiple sclerosis	0.000274	0.00124	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—MYC—multiple sclerosis	0.000274	0.00124	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TGFB1—multiple sclerosis	0.000273	0.00123	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000269	0.00122	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—CD80—multiple sclerosis	0.000268	0.00121	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—TNF—multiple sclerosis	0.000266	0.0012	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—RPL5—multiple sclerosis	0.000266	0.0012	CbGpPWpGaD
Fulvestrant—Dizziness—Methotrexate—multiple sclerosis	0.000266	0.000636	CcSEcCtD
Fulvestrant—Vomiting—Methotrexate—multiple sclerosis	0.000256	0.000612	CcSEcCtD
Fulvestrant—Rash—Methotrexate—multiple sclerosis	0.000254	0.000607	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—MAPK1—multiple sclerosis	0.000254	0.00114	CbGpPWpGaD
Fulvestrant—Dermatitis—Methotrexate—multiple sclerosis	0.000253	0.000606	CcSEcCtD
Fulvestrant—Headache—Methotrexate—multiple sclerosis	0.000252	0.000603	CcSEcCtD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000252	0.00114	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—multiple sclerosis	0.000244	0.0011	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	0.000243	0.0011	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—HNRNPA1—multiple sclerosis	0.000243	0.0011	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—U2AF2—multiple sclerosis	0.000243	0.0011	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	0.000243	0.0011	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—PGR—multiple sclerosis	0.000241	0.00109	CbGpPWpGaD
Fulvestrant—Nausea—Methotrexate—multiple sclerosis	0.000239	0.000571	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	0.000238	0.00107	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—BCHE—multiple sclerosis	0.000238	0.00107	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—IL6—multiple sclerosis	0.000236	0.00107	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000235	0.00106	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—VDR—multiple sclerosis	0.00023	0.00104	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.000227	0.00102	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—TYK2—multiple sclerosis	0.000226	0.00102	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—PGR—multiple sclerosis	0.000219	0.000991	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—IL6—multiple sclerosis	0.000215	0.000971	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—PGR—multiple sclerosis	0.000209	0.000946	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—IL6—multiple sclerosis	0.000206	0.00093	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000202	0.000911	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—ZFP36L1—multiple sclerosis	0.000192	0.000866	CbGpPWpGaD
Fulvestrant—ESRRA—Generic Transcription Pathway—MYC—multiple sclerosis	0.00019	0.000858	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000184	0.000831	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—LINGO1—multiple sclerosis	0.000182	0.000822	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—APOE—multiple sclerosis	0.000179	0.000809	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—ALB—multiple sclerosis	0.000175	0.00079	CbGpPWpGaD
Fulvestrant—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000175	0.000789	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—BCHE—multiple sclerosis	0.000174	0.000785	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—VDR—multiple sclerosis	0.000168	0.000759	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TAGAP—multiple sclerosis	0.000158	0.000713	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—POMC—multiple sclerosis	0.000154	0.000695	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—VDR—multiple sclerosis	0.000153	0.000692	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PABPC1—multiple sclerosis	0.000149	0.000672	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	0.000148	0.000669	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—VDR—multiple sclerosis	0.000146	0.000661	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	0.000145	0.000654	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—MAPK1—multiple sclerosis	0.000144	0.000651	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—APOE—multiple sclerosis	0.000143	0.000646	CbGpPWpGaD
Fulvestrant—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000142	0.00064	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ALB—multiple sclerosis	0.00014	0.000633	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—MYC—multiple sclerosis	0.000139	0.000627	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—S1PR1—multiple sclerosis	0.000138	0.000623	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—RPL5—multiple sclerosis	0.000134	0.000606	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GPC5—multiple sclerosis	0.000134	0.000606	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—POMC—multiple sclerosis	0.000123	0.000555	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	0.000123	0.000554	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	0.000122	0.000553	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—MYC—multiple sclerosis	0.000121	0.000546	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	0.00012	0.000542	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—RGS1—multiple sclerosis	0.000117	0.00053	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.000114	0.000516	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ALB—multiple sclerosis	0.000112	0.000506	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GPR65—multiple sclerosis	0.000111	0.000502	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—IL6—multiple sclerosis	0.000111	0.0005	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—PGR—multiple sclerosis	0.000106	0.000477	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—APOE—multiple sclerosis	0.000105	0.000472	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCR1—multiple sclerosis	0.000102	0.000459	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCL13—multiple sclerosis	0.000102	0.000459	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MYC—multiple sclerosis	9.14e-05	0.000413	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—POMC—multiple sclerosis	8.99e-05	0.000406	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ALB—multiple sclerosis	8.19e-05	0.00037	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SRM—multiple sclerosis	8.12e-05	0.000367	CbGpPWpGaD
Fulvestrant—CYP3A4—Biological oxidations—POMC—multiple sclerosis	7.52e-05	0.00034	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—VDR—multiple sclerosis	7.38e-05	0.000333	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCL3—multiple sclerosis	7.25e-05	0.000327	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTGER4—multiple sclerosis	6.97e-05	0.000315	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PGR—multiple sclerosis	6.87e-05	0.00031	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCR3—multiple sclerosis	6.74e-05	0.000304	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MYC—multiple sclerosis	6.68e-05	0.000302	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CD28—multiple sclerosis	6.67e-05	0.000301	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCR2—multiple sclerosis	6.55e-05	0.000296	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MYC—multiple sclerosis	6.09e-05	0.000275	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CNR1—multiple sclerosis	6.05e-05	0.000273	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MYC—multiple sclerosis	5.82e-05	0.000263	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	5.72e-05	0.000258	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	5.72e-05	0.000258	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CXCL10—multiple sclerosis	5.44e-05	0.000246	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GPC5—multiple sclerosis	5.23e-05	0.000236	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CD86—multiple sclerosis	4.76e-05	0.000215	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCL5—multiple sclerosis	4.69e-05	0.000212	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—SPP1—multiple sclerosis	4.34e-05	0.000196	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—RRM1—multiple sclerosis	4.33e-05	0.000196	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCR5—multiple sclerosis	4.22e-05	0.000191	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL2RA—multiple sclerosis	4.16e-05	0.000188	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—APOE—multiple sclerosis	3.84e-05	0.000173	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CD80—multiple sclerosis	3.47e-05	0.000157	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—POMC—multiple sclerosis	3.3e-05	0.000149	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CCL2—multiple sclerosis	3.23e-05	0.000146	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MYC—multiple sclerosis	2.93e-05	0.000132	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TYK2—multiple sclerosis	2.93e-05	0.000132	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—BCHE—multiple sclerosis	2.49e-05	0.000112	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL2—multiple sclerosis	2.44e-05	0.00011	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MMP9—multiple sclerosis	2.31e-05	0.000104	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—STAT3—multiple sclerosis	2.05e-05	9.27e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MYC—multiple sclerosis	1.91e-05	8.61e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TGFB1—multiple sclerosis	1.9e-05	8.59e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MAPK1—multiple sclerosis	1.87e-05	8.43e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—APOE—multiple sclerosis	1.5e-05	6.76e-05	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—IL6—multiple sclerosis	1.43e-05	6.48e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—POMC—multiple sclerosis	1.29e-05	5.81e-05	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ALB—multiple sclerosis	1.17e-05	5.3e-05	CbGpPWpGaD
